Adherents say DMT opens a hyperspace of real beings; clinical records log such reports and test psychedelics as drugs. Terence McKenna described "self-transforming machine elves" met under the drug. A psychiatrist who gave DMT to volunteers in New Mexico later wrote that it might let the brain perceive realms inhabited by conscious entities. Beside those claims stand a Johns Hopkins psilocybin trial, a Hopkins survey of DMT entity encounters, a breakthrough designation for psilocybin therapy, and federal guidance on psychedelic trials. Each is set out as its authors printed it.
McKenna's account, 1983
In a talk at Esalen in December 1983, given at a conference on consciousness and quantum physics and printed in edited form in his book The Archaic Revival, McKenna said that smoked DMT takes effect in about fifteen seconds and brings one to a place that feels underground or domed. There one meets entities that he and his brother had described in The Invisible Landscape as "self-transforming machine elves." He called them "hyperdimensional machine-elf entities" that "bathe one in love," and said they are "like fractal reflections of some previously hidden and suddenly autonomous part of one's own psyche." He said they emit a language "that cannot be Englished." He placed the realm in what he called hyperspace, meaning dream, the psilocybin trance, the quantum foundation of being, the human future, and death. "My testimony is that magic is alive in hyperspace," he said. "It is not necessary to believe me, only to form a relationship with these hallucinogenic plants."
McKenna, Esalen, December 1983: https://www.jacobsm.com/deoxy/deoxy.org/t_thc.htm
Strassman's DMT studies, in his words
On his own site, Rick Strassman writes that in 1990 he began the first new human research with psychedelic drugs in the United States in over 20 years, giving about 400 doses of DMT to 60 volunteers over five years at the University of New Mexico School of Medicine, where he was a tenured associate professor of psychiatry. He writes that he was drawn to DMT because it is present in all our bodies, that he wondered whether the pineal gland was involved in naturally occurring "psychedelic" states, and that only later did he consider DMT's role in the "alien abduction" experience. The studies were not meant to be therapeutic and ended in 1995. In DMT: The Spirit Molecule, he writes, he includes "highly speculative ideas," among them the proposal that DMT can allow our brains to perceive dark matter or parallel universes, "realms of existence inhabited by conscious entities." He also writes that DMT has no beneficial effects in and of itself, and that the context in which people take it is at least as important.
Rick Strassman, DMT: The Spirit Molecule: https://www.rickstrassman.com/publications/the-spirit-molecule/
The 2006 Hopkins psilocybin trial
A double-blind study by Roland Griffiths and colleagues, published in Psychopharmacology in August 2006 and listed by Johns Hopkins University, gave 30 hallucinogen-naive adults who took part in religious or spiritual activities a high dose of psilocybin and, in another session, methylphenidate as a comparison. The abstract reports a range of perceptual changes and labile moods, including anxiety, and higher scores on measures of mystical experience. At two months volunteers rated the psilocybin session as having substantial personal meaning and spiritual significance, and community observers rated changes consistent with theirs. The authors concluded that under supportive conditions psilocybin occasioned experiences similar to spontaneously occurring mystical experiences.
Griffiths et al., 2006: https://pure.johnshopkins.edu/en/publications/psilocybin-can-occasion-mystical-type-experiences-having-substant-4/
A survey of DMT entity encounters
In the Journal of Psychopharmacology in September 2020, Alan Davis and colleagues, in a paper listed by Johns Hopkins University, reported an online survey of 2,561 people about their single most memorable entity encounter after inhaling DMT. The most common labels for the entity were being, guide, spirit, alien and helper. Forty-one percent reported fear, yet the strongest emotions were love, kindness and joy. Most respondents endorsed that the entity was conscious, intelligent and benevolent, existed in some real but different dimension of reality, and continued to exist afterward; 69 percent reported receiving a message. More than half of those who were atheists before no longer identified as atheist. The authors wrote that the encounters resemble non-drug accounts in religious, alien abduction and near-death settings.
Davis et al., 2020: https://pure.johnshopkins.edu/en/publications/survey-of-entity-encounter-experiences-occasioned-by-inhaled-nn-d/
A breakthrough designation
On 23 October 2018, COMPASS Pathways announced that the US Food and Drug Administration had granted Breakthrough Therapy designation to its psilocybin therapy for treatment-resistant depression. The release explains that the agency gives the designation when preliminary clinical evidence shows a drug may demonstrate substantial improvement over available therapy. It credits the Heffter Research Institute with funding early studies at Johns Hopkins, New York University and Harbor-UCLA, and quotes Robin Carhart-Harris that a 2015 Imperial College study gave psilocybin to 19 patients and found promising signals of efficacy and safety.
COMPASS Pathways, 23 October 2018: https://www.prnewswire.com/news-releases/compass-pathways-receives-fda-breakthrough-therapy-designation-for-psilocybin-therapy-for-treatment-resistant-depression-834088100.html
The agency's own caution
On 23 June 2023 the FDA issued its first draft guidance on clinical trials with psychedelic drugs, covering classic psychedelics such as psilocybin and LSD and entactogens such as MDMA. Tiffany Farchione, director of its psychiatry division, said the drugs "show initial promise" for mood, anxiety and substance use disorders but "are still investigational products." The release notes that the drugs may produce hallucinations and potential for abuse, that Schedule I substances remain under Drug Enforcement Administration rules, and that the standard of evidence for effectiveness is the same as for all other drugs.
FDA, 23 June 2023: https://www.fda.gov/news-events/press-announcements/fda-issues-first-draft-guidance-clinical-trials-psychedelic-drugs
Beside the claim
The adherent claim, in these doors, is that DMT gives access to a hyperspace whose beings are encountered, not imagined; McKenna offers it as testimony and Strassman as speculation. The clinical records print something narrower. The Hopkins survey is a record of what 2,561 users reported and believed about their encounters. The 2006 trial measures mystical-type experience, and the designation and the guidance treat psilocybin and its relatives as investigational medicines under the usual standard of proof.


